Bide Pharmatech Co. Ltd. A (688073) - Net Assets
Based on the latest financial reports, Bide Pharmatech Co. Ltd. A (688073) has net assets worth CN¥2.10 Billion CNY (≈ $307.29 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.54 Billion ≈ $371.99 Million USD) and total liabilities (CN¥442.16 Million ≈ $64.70 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore total assets of Bide Pharmatech Co. Ltd. A for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.10 Billion |
| % of Total Assets | 82.61% |
| Annual Growth Rate | 41.22% |
| 5-Year Change | 225.25% |
| 10-Year Change | N/A |
| Growth Volatility | 89.55 |
Bide Pharmatech Co. Ltd. A - Net Assets Trend (2020–2025)
This chart illustrates how Bide Pharmatech Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Check Bide Pharmatech Co. Ltd. A tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Bide Pharmatech Co. Ltd. A (2020–2025)
The table below shows the annual net assets of Bide Pharmatech Co. Ltd. A from 2020 to 2025. For live valuation and market cap data, see Bide Pharmatech Co. Ltd. A market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.05 Billion ≈ $299.31 Million |
+0.90% |
| 2024-12-31 | CN¥2.03 Billion ≈ $296.63 Million |
-2.99% |
| 2023-12-31 | CN¥2.09 Billion ≈ $305.77 Million |
+0.64% |
| 2022-12-31 | CN¥2.08 Billion ≈ $303.81 Million |
+230.15% |
| 2021-12-31 | CN¥628.86 Million ≈ $92.02 Million |
+72.64% |
| 2020-12-31 | CN¥364.26 Million ≈ $53.30 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bide Pharmatech Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 32365811947.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥319.83 Million | 15.64% |
| Other Components | CN¥1.73 Billion | 84.36% |
| Total Equity | CN¥2.05 Billion | 100.00% |
Bide Pharmatech Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Bide Pharmatech Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ITE Tech Inc
TW:3014
|
$682.65 Million |
|
Chongqing Wangbian Electric (Group) Corp. Ltd.
SHG:603191
|
$682.82 Million |
|
Lotte Tour Dev
KO:032350
|
$682.94 Million |
|
Xilong Chemical Co Ltd
SHE:002584
|
$683.37 Million |
|
Shenzhen Anche Technologies Co Ltd
SHE:300572
|
$682.56 Million |
|
iQIYI Inc
F:IQ8
|
$682.34 Million |
|
Dodla Dairy Limited
NSE:DODLA
|
$682.11 Million |
|
Zhuzhou Tianqiao Crane Co Ltd
SHE:002523
|
$682.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bide Pharmatech Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,027,122,464 to 2,045,395,005, a change of 18,272,542 (0.9%).
- Net income of 151,739,652 contributed positively to equity growth.
- Dividend payments of 79,786,387 reduced retained earnings.
- Other factors decreased equity by 53,680,723.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥151.74 Million | +7.42% |
| Dividends Paid | CN¥79.79 Million | -3.9% |
| Other Changes | CN¥-53.68 Million | -2.62% |
| Total Change | CN¥- | 0.90% |
Book Value vs Market Value Analysis
This analysis compares Bide Pharmatech Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.28x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 8.88x to 2.28x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | CN¥5.78 | CN¥51.33 | x |
| 2021-12-31 | CN¥9.23 | CN¥51.33 | x |
| 2022-12-31 | CN¥22.84 | CN¥51.33 | x |
| 2023-12-31 | CN¥22.99 | CN¥51.33 | x |
| 2024-12-31 | CN¥22.30 | CN¥51.33 | x |
| 2025-12-31 | CN¥22.51 | CN¥51.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bide Pharmatech Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.42%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.46%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 1.23x
- Recent ROE (7.42%) is below the historical average (9.53%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 16.20% | 15.07% | 0.74x | 1.46x | CN¥22.58 Million |
| 2021 | 15.52% | 16.10% | 0.67x | 1.44x | CN¥34.69 Million |
| 2022 | 7.03% | 17.51% | 0.35x | 1.14x | CN¥-61.64 Million |
| 2023 | 5.24% | 10.04% | 0.45x | 1.16x | CN¥-99.38 Million |
| 2024 | 5.79% | 10.66% | 0.46x | 1.19x | CN¥-85.29 Million |
| 2025 | 7.42% | 11.46% | 0.53x | 1.23x | CN¥-52.80 Million |
Industry Comparison
This section compares Bide Pharmatech Co. Ltd. A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,133,881,544
- Average return on equity (ROE) among peers: 2.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bide Pharmatech Co. Ltd. A (688073) | CN¥2.10 Billion | 16.20% | 0.21x | $682.64 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $868.76 Million | 4.89% | 3.05x | $639.13 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $775.01 Million | 2.45% | 0.87x | $378.07 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $5.07 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $662.32 Million | 12.10% | 0.68x | $2.59 Billion |
| Wedge Industrial Co Ltd (000534) | $692.08 Million | 2.78% | 1.05x | $1.97 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $3.19 Billion | 14.61% | 0.55x | $13.23 Billion |
| Hainan Haiyao Co Ltd (000566) | $1.49 Billion | 5.19% | 0.85x | $1.11 Billion |
| Tus Pharmaceutical Group Co Ltd (000590) | $231.22 Million | -38.13% | 1.23x | $302.41 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $1.75 Billion | 0.46% | 2.42x | $956.43 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.35 Billion | 7.34% | 0.44x | $3.16 Billion |
About Bide Pharmatech Co. Ltd. A
Bide Pharmatech Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. Its products are used in life sciences, organic chemistry, analytical chemistry, and other applications. The company was founded in 2007 and is based in Shanghai, China.